About This Initiative
Clostridioides difficile infection (CDI) is the most common healthcare-associated infection and the most common cause of mortality in patients with gastroenteritis in the United States. Historically, approximately one in four patients suffer from recurrent CDI, which is associated with increased morbidity, mortality, healthcare costs, and decreased quality of life. . Recent updates to national guidelines place a greater emphasis on recurrence prevention. This series explores these guideline updates and their application in special patient populations, with a focus on those at high risk for recurrent CDI.
Applying the Guidelines on Recurrent Clostridioides difficile Infection in Special Patient Populations
This 1.5-hour interprofessional educational activity examines recent data on Clostridioides difficile infection pharmacotherapy and uses a case-based approach to apply recent guideline recommendations to special patient populations, with a focus on those at high risk for recurrent CDI.
On-demand Ask the Experts Activity
Using Pharmacology, Pharmacokinetics, and Pharmacoeconomics to Demystify Newer Strategies for C. difficile
This on-demand activity will address questions and comments from previous activity participants.
Engaging the Experts Podcast
Learn from experts in the field on contemporary diagnosis and management of C. diff infection. Topics include new diagnostic strategies and best treatment plans for our patients.